Trade Report: Today, JPMorgan Chase & Co. Reiterates $34.00 Price Target for Juno Therapeutics Inc (JUNO)

Today, JPMorgan Chase & Co. Reiterates $34.00 Price Target for Juno Therapeutics Inc (JUNO)

Juno Therapeutics Inc (NASDAQ:JUNO) has been assigned a $34.00 price objective by research analysts at JPMorgan Chase & Co. in a report issued on Thursday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 47.76% from the stock’s previous close.

Several other analysts have also recently commented on JUNO. Maxim Group reduced their target price on shares of Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating for the company in a research note on Friday, August 5th. FBR & Co set a $61.00 target price on shares of Juno Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Vetr cut shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 target price for the company. in a research note on Tuesday, August 16th. Standpoint Research started coverage on shares of Juno Therapeutics in a research note on Thursday, August 25th. They issued a “buy” rating and a $47.00 target price for the company. Finally, BTIG Research started coverage on shares of Juno Therapeutics in a research note on Tuesday, August 30th. They issued a “sell” rating and a $23.00 target price for the company. Six analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Juno Therapeutics has a consensus rating of “Buy” and an average price target of $41.13.

Juno Therapeutics (NASDAQ:JUNO) traded up 1.99% during trading on Thursday, reaching $23.01. 3,843,132 shares of the company’s stock traded hands. The firm’s market capitalization is $2.36 billion. Juno Therapeutics has a 1-year low of $19.41 and a 1-year high of $57.82. The firm has a 50 day moving average of $27.52 and a 200 day moving average of $32.91.

Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The firm had revenue of $20.80 million for the quarter, compared to the consensus estimate of $10.98 million. During the same period in the previous year, the business earned ($0.26) EPS. The business’s revenue for the quarter was up 1200.0% on a year-over-year basis. Equities analysts forecast that Juno Therapeutics will post ($2.54) EPS for the current year.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the transaction, the executive vice president now directly owns 48,640 shares in the company, valued at approximately $1,174,169.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Hans Edgar Bishop sold 23,042 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $30.06, for a total transaction of $692,642.52. Following the transaction, the chief executive officer now owns 2,541,151 shares of the company’s stock, valued at $76,386,999.06. The disclosure for this sale can be found here.

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Juno Therapeutics by 14.8% in the second quarter. Vanguard Group Inc. now owns 5,471,650 shares of the biopharmaceutical company’s stock valued at $210,331,000 after buying an additional 707,140 shares during the period. BlackRock Fund Advisors increased its position in Juno Therapeutics by 3.4% in the third quarter. BlackRock Fund Advisors now owns 2,031,736 shares of the biopharmaceutical company’s stock valued at $60,972,000 after buying an additional 67,333 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Juno Therapeutics by 5.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,757,750 shares of the biopharmaceutical company’s stock valued at $52,750,000 after buying an additional 94,570 shares during the period. State Street Corp increased its position in Juno Therapeutics by 36.1% in the second quarter. State Street Corp now owns 1,658,792 shares of the biopharmaceutical company’s stock valued at $63,764,000 after buying an additional 440,324 shares during the period. Finally, BB Biotech AG increased its position in Juno Therapeutics by 7.7% in the third quarter. BB Biotech AG now owns 1,405,000 shares of the biopharmaceutical company’s stock valued at $42,164,000 after buying an additional 100,000 shares during the period.

About Juno Therapeutics

Related posts

Leave a Comment